Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Return on Assets (2019 - 2025)

Historic Return on Assets for BioNexus Gene Lab (BGLC) over the last 7 years, with Q3 2025 value amounting to 0.27%.

  • BioNexus Gene Lab's Return on Assets fell 1900.0% to 0.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.27%, marking a year-over-year decrease of 1900.0%. This contributed to the annual value of 0.15% for FY2024, which is 1100.0% up from last year.
  • According to the latest figures from Q3 2025, BioNexus Gene Lab's Return on Assets is 0.27%, which was down 1900.0% from 0.31% recorded in Q2 2025.
  • BioNexus Gene Lab's Return on Assets' 5-year high stood at 0.14% during Q4 2021, with a 5-year trough of 0.31% in Q2 2025.
  • Its 5-year average for Return on Assets is 0.08%, with a median of 0.06% in 2023.
  • As far as peak fluctuations go, BioNexus Gene Lab's Return on Assets crashed by -10800bps in 2021, and later surged by 2300bps in 2024.
  • BioNexus Gene Lab's Return on Assets (Quarter) stood at 0.14% in 2021, then crashed by -122bps to 0.03% in 2022, then tumbled by -644bps to 0.23% in 2023, then soared by 36bps to 0.14% in 2024, then crashed by -86bps to 0.27% in 2025.
  • Its Return on Assets stands at 0.27% for Q3 2025, versus 0.31% for Q2 2025 and 0.21% for Q1 2025.